Healthcare CRO Services Market by Type (Early Phase Development, Clinical Development Services, Laboratory Services, and Consulting Services), Therapeutic Area (Oncology, CNS Disorder, Cardiovascular Disease, Metabolic Disease, Infectious Disease, Diabetes, and Others), and End-User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes): Global Opportunity Analysis and Industry Forecast, 2019–2026
The global healthcare contract research organization (CRO) services market was valued at $38,996.9 million in 2018 and is expected to reach $66,036.6 million by 2026, registering a CAGR of 6.9% from 2019 to 2026. Contract research organizations (CROs) are outsourcing companies or groups that conduct specific and focused R&D clinical trials for the pharmaceutical or biotech industry. They possess well-experienced professionals that offer preclinical, clinical, and regulatory activities for drug and medical devices development, and their commercialization. These organizations can range from international full-service groups to small or niche service providing groups. In addition, CROs provide the experience of moving a novel drug, molecule, or a drug from its nascent phase to marketing approval, without any involvement of a sponsor for these services.
Surge in R&D for the development of novel drugs and medical devices and rise in healthcare expenditure are the major factorsthat drive the market growth. Moreover, CROs help in saving time and extra cost of manufacturers as it reduces the time to conduct a trial compared to the time taken for doing the same trials in-house, whichleadsto significant cost savings. However, penetrating competition in the market and dearth of skilled professionals are the major factors anticipated to hamper the market growth. Moreover, rise in the biotech and pharmaceutical sector in developing economies is expected to create lucrative opportunities for the market.
The market is segmented on the basis of service type, therapeutic area, end-users, and region. By service type, it is categorized into early phase development, clinical development services, laboratory services, and consulting services. By therapeutic area, it is segmented into oncology, CNS disorder, cardiovascular disease, metabolic disease, infectious disease, diabetes, and others. By end-users it is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
By Service Type
Surge in R&D for the development of novel drugs and medical devices and rise in healthcare expenditure are the major factorsthat drive the market growth. Moreover, CROs help in saving time and extra cost of manufacturers as it reduces the time to conduct a trial compared to the time taken for doing the same trials in-house, whichleadsto significant cost savings. However, penetrating competition in the market and dearth of skilled professionals are the major factors anticipated to hamper the market growth. Moreover, rise in the biotech and pharmaceutical sector in developing economies is expected to create lucrative opportunities for the market.
The market is segmented on the basis of service type, therapeutic area, end-users, and region. By service type, it is categorized into early phase development, clinical development services, laboratory services, and consulting services. By therapeutic area, it is segmented into oncology, CNS disorder, cardiovascular disease, metabolic disease, infectious disease, diabetes, and others. By end-users it is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
- It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
By Service Type
- Early Phase Development
- Clinical Research Services
- Laboratory Services
- Consulting Services
- Oncology
- CNS Disorder
- Cardiovascular Disease
- Metabolic Disease
- Infectious Disease
- Diabetes
- Others
- Pharmaceutical Companies
- Medical Device Companies
- Academic Institutes
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- IQVIA
- PRA Health Sciences
- ICON
- Syneos Health
- Evotec
- Charles River
- Medpace
- Labcorp
- Biotelemetry
- Syngene
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Research methodology
1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Porter's five forces analysis
3.1. Key Findings
3.1.1. Top Investment Pockets
3.2. Top player positioning
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Rise in R&D investment
3.3.1.2. Significant increase in cancer incidence across the globe
3.3.2. Restraints
3.3.2.1. Dearth of skilled labors/healthcare professionals
3.3.3. Opportunities
3.3.3.1. Various growth opportunities in emerging economies
CHAPTER 4: HEALTHCARE CRO SERVICES MARKET, BY SERVICE TYPE
4.1. Overview
4.1.1. Market size and forecast, by service type
4.2. Early phase development
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Clinical development services
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Laboratory Services
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Consulting Services
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: CRO SERVICES MARKET, BY THERAPEUTIC AREA
5.1. Overview
5.1.1. Market size and forecast, by therapeutic area
5.2. Oncology
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. CNS Disorder
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Cardiovascular disease
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Metabolic disease
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Infectious disease
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Diabetes
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
5.8. Others
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
CHAPTER 6: CRO SERVICES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast, by end user
6.2. Pharmaceutical & biopharmaceutical companies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Medical device companies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Academic institutes
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: CRO SERVICES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by service type
7.2.4. Market size and forecast, by therapeutic area
7.2.5. Market size and forecast, by end user
7.2.5.1. U.S. market size and forecast, by service type
7.2.5.2. U.S. market size and forecast, by therapeutic area
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by service type
7.2.5.5. Canada market size and forecast, by therapeutic area
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by service type
7.2.5.8. Mexico market size and forecast, by therapeutic area
7.2.5.9. Mexico CRO services MARKET, by end user
7.3. Europe
7.3.1. Key market trends
7.3.2. Market size and forecast, by country
7.3.3. Market size and forecast, by service type
7.3.4. Market size and forecast, by therapeutic area
7.3.5. Market size and forecast, by end user
7.3.5.1. France market size and forecast, by service type
7.3.5.2. France market size and forecast, by therapeutic area
7.3.5.3. France market size and forecast, by end user
7.3.5.4. UK market size and forecast, by service type
7.3.5.5. UK market size and forecast, by therapeutic area
7.3.5.6. UK market size and forecast, by end user
7.3.5.7. Germany market size and forecast, by service type
7.3.5.8. Germany market size and forecast, by therapeutic area
7.3.5.9. Germany market size and forecast, by end user
7.3.5.10. Spain market size and forecast, by service type
7.3.5.11. Spain market size and forecast, by therapeutic area
7.3.5.12. Spain market size and forecast, by end user
7.3.5.13. Rest of Europe market size and forecast, by service type
7.3.5.14. Rest of Europe market size and forecast, by therapeutic area
7.3.5.15. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by therapeutic area
7.4.4. Market size and forecast, by end user
7.4.4.1. Japan market size and forecast, by service type
7.4.4.2. Japan market size and forecast, by therapeutic area
7.4.4.3. Japan market size and forecast, by end user
7.4.4.4. China market size and forecast, by service type
7.4.4.5. China market size and forecast, by therapeutic area
7.4.4.6. China market size and forecast, by end user
7.4.4.7. India market size and forecast, by service type
7.4.4.8. India market size and forecast, by therapeutic area
7.4.4.9. India market size and forecast, by end user
7.4.4.10. Australia market size and forecast, by service type
7.4.4.11. Australia market size and forecast, by therapeutic area
7.4.4.12. Australia market size and forecast, by end user
7.4.4.13. Rest of Asia-Pacific market size and forecast, by service type
7.4.4.14. Rest of Asia-Pacific market size and forecast, by therapeutic area
7.4.4.15. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by service type
7.5.4. Market size and forecast, by therapeutic area
7.5.5. Market size and forecast, by end user
7.5.5.1. Brazil market size and forecast, by service type
7.5.5.2. Brazil market size and forecast, by therapeutic area
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. South Africa market size and forecast, by service type
7.5.5.5. South Africa market size and forecast, by therapeutic area
7.5.5.6. South Africa market size and forecast, by end user
7.5.5.7. Saudi Arabia market size and forecast, by service type
7.5.5.8. Saudi Arabia market size and forecast, by therapeutic area
7.5.5.9. Saudi Arabia market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by service type
7.5.5.11. Rest of LAMEA market size and forecast, by therapeutic area
7.5.5.12. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. BioTelemetry Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. CHARLES RIVER LABORATORIES Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. ICON.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. IQVIA
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Evotec SE
8.5.1. Company overview
8.5.2. Operating business segments
8.5.3. Product portfolio
8.5.4. Business performance
8.6. Laboratory Corporation of America Holdings
8.6.1. Company overview
8.6.2. Operating business segments
8.6.3. Product portfolio
8.6.4. Business performance
8.7. Medpace, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. PRA Health Science
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Syngene International Limited
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. Syneos Health
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Research methodology
1.3.1. Secondary research
1.3.2. Primary research
1.3.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Porter's five forces analysis
3.1. Key Findings
3.1.1. Top Investment Pockets
3.2. Top player positioning
3.3. Market dynamics
3.3.1. Drivers
3.3.1.1. Rise in R&D investment
3.3.1.2. Significant increase in cancer incidence across the globe
3.3.2. Restraints
3.3.2.1. Dearth of skilled labors/healthcare professionals
3.3.3. Opportunities
3.3.3.1. Various growth opportunities in emerging economies
CHAPTER 4: HEALTHCARE CRO SERVICES MARKET, BY SERVICE TYPE
4.1. Overview
4.1.1. Market size and forecast, by service type
4.2. Early phase development
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Clinical development services
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Laboratory Services
4.4.1. Key market trends and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Consulting Services
4.5.1. Key market trends and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
CHAPTER 5: CRO SERVICES MARKET, BY THERAPEUTIC AREA
5.1. Overview
5.1.1. Market size and forecast, by therapeutic area
5.2. Oncology
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. CNS Disorder
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Cardiovascular disease
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Metabolic disease
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Infectious disease
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Diabetes
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
5.8. Others
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by country
CHAPTER 6: CRO SERVICES MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast, by end user
6.2. Pharmaceutical & biopharmaceutical companies
6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country
6.3. Medical device companies
6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country
6.4. Academic institutes
6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: CRO SERVICES MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by country
7.2.3. Market size and forecast, by service type
7.2.4. Market size and forecast, by therapeutic area
7.2.5. Market size and forecast, by end user
7.2.5.1. U.S. market size and forecast, by service type
7.2.5.2. U.S. market size and forecast, by therapeutic area
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by service type
7.2.5.5. Canada market size and forecast, by therapeutic area
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by service type
7.2.5.8. Mexico market size and forecast, by therapeutic area
7.2.5.9. Mexico CRO services MARKET, by end user
7.3. Europe
7.3.1. Key market trends
7.3.2. Market size and forecast, by country
7.3.3. Market size and forecast, by service type
7.3.4. Market size and forecast, by therapeutic area
7.3.5. Market size and forecast, by end user
7.3.5.1. France market size and forecast, by service type
7.3.5.2. France market size and forecast, by therapeutic area
7.3.5.3. France market size and forecast, by end user
7.3.5.4. UK market size and forecast, by service type
7.3.5.5. UK market size and forecast, by therapeutic area
7.3.5.6. UK market size and forecast, by end user
7.3.5.7. Germany market size and forecast, by service type
7.3.5.8. Germany market size and forecast, by therapeutic area
7.3.5.9. Germany market size and forecast, by end user
7.3.5.10. Spain market size and forecast, by service type
7.3.5.11. Spain market size and forecast, by therapeutic area
7.3.5.12. Spain market size and forecast, by end user
7.3.5.13. Rest of Europe market size and forecast, by service type
7.3.5.14. Rest of Europe market size and forecast, by therapeutic area
7.3.5.15. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by country
7.4.3. Market size and forecast, by therapeutic area
7.4.4. Market size and forecast, by end user
7.4.4.1. Japan market size and forecast, by service type
7.4.4.2. Japan market size and forecast, by therapeutic area
7.4.4.3. Japan market size and forecast, by end user
7.4.4.4. China market size and forecast, by service type
7.4.4.5. China market size and forecast, by therapeutic area
7.4.4.6. China market size and forecast, by end user
7.4.4.7. India market size and forecast, by service type
7.4.4.8. India market size and forecast, by therapeutic area
7.4.4.9. India market size and forecast, by end user
7.4.4.10. Australia market size and forecast, by service type
7.4.4.11. Australia market size and forecast, by therapeutic area
7.4.4.12. Australia market size and forecast, by end user
7.4.4.13. Rest of Asia-Pacific market size and forecast, by service type
7.4.4.14. Rest of Asia-Pacific market size and forecast, by therapeutic area
7.4.4.15. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by country
7.5.3. Market size and forecast, by service type
7.5.4. Market size and forecast, by therapeutic area
7.5.5. Market size and forecast, by end user
7.5.5.1. Brazil market size and forecast, by service type
7.5.5.2. Brazil market size and forecast, by therapeutic area
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. South Africa market size and forecast, by service type
7.5.5.5. South Africa market size and forecast, by therapeutic area
7.5.5.6. South Africa market size and forecast, by end user
7.5.5.7. Saudi Arabia market size and forecast, by service type
7.5.5.8. Saudi Arabia market size and forecast, by therapeutic area
7.5.5.9. Saudi Arabia market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by service type
7.5.5.11. Rest of LAMEA market size and forecast, by therapeutic area
7.5.5.12. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. BioTelemetry Inc.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. CHARLES RIVER LABORATORIES Inc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.3. ICON.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. IQVIA
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.5. Evotec SE
8.5.1. Company overview
8.5.2. Operating business segments
8.5.3. Product portfolio
8.5.4. Business performance
8.6. Laboratory Corporation of America Holdings
8.6.1. Company overview
8.6.2. Operating business segments
8.6.3. Product portfolio
8.6.4. Business performance
8.7. Medpace, Inc.
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. PRA Health Science
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Syngene International Limited
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.10. Syneos Health
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
LIST OF TABLES
TABLE 01. GLOBAL CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 02. HEALTHCARE CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT, BY REGION, 2018–2026 ($MILLION)
TABLE 03. HEALTHCARE CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 04. CLINICAL DEVELOPMENT SERVICES MARKET BY REGION 2018–2026 ($MILLION)
TABLE 05. CLINICAL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 06. HEALTHCARE CRO SERVICES MARKET FOR LABORATORY SERVICES MARKET BY REGION 2018–2026 ($MILLION)
TABLE 07. HEALTHCARE CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 08. HEALTHCARE CRO SERVICES MARKET FOR CONSULTING SERVICES BY REGION 2018–2026 ($MILLION)
TABLE 09. HEALTHCARE CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10. GLOBAL CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 11. ONCOLOGY HEALTHCARE CRO SERVICES, BY REGION, 2018–2026 ($MILLION)
TABLE 12. CRO SERVICES MARKET FOR CNS DISORDER, BY REGION, 2018–2026 ($MILLION)
TABLE 13. CRO SERVICES MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 14. CRO SERVICES MARKET FOR METABOLIC DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 15. CRO SERVICES MARKET FOR INFECTIOUS DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 16. HEALTHCARE CRO SERVICES MARKET FOR DIABETES, BY REGION, 2018–2026 ($MILLION)
TABLE 17. CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREA, BY REGION, 2018–2026 ($MILLION)
TABLE 18. GLOBAL CRO SERVICES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 19. CRO SERVICES MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018–2026 ($MILLION)
TABLE 20. CRO SERVICES MARKET, FOR MEDICAL DEVICE, BY REGION, 2018–2026 ($MILLION)
TABLE 21. CARDIOVASCULAR DISEASE CRO SERVICES MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 2018–2026 ($MILLION)
TABLE 22. CRO SERVICES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 23. NORTH AMERICA CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 24. NORTH AMERICA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 25. NORTH AMERICA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 26. NORTH AMERICA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 27. U.S. CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 28. U.S. CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 29. U.S. CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 30. CANADA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 31. CANADA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 32. CANADA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 33. MEXICO CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 34. MEXICO CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 35. MEXICO CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 36. EUROPE CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 37. EUROPE CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 38. EUROPE CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 39. EUROPE CRO SERVICES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 40. FRANCE CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 41. FRANCE CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 42. FRANCE CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 43. UK CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 44. UK CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 45. U.K CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 46. GERMANY CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 47. GERMANY CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 48. GERMANY CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 49. SPAIN CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 50. SPAIN CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 51. SPAIN CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 52. REST OF EUROPE CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 53. REST OF EUROPE CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 54. REST OF EUROPE CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 55. ASIA-PACIFIC CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 56. ASIA-PACIFIC CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 57. ASIA-PACIFIC CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 58. ASIA-PACIFIC CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 59. JAPAN CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 60. JAPAN CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 61. JAPAN CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 62. CHINA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 63. CHINA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 64. CHINA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 65. INDIA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 66. INDIA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 67. INDIA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 68. AUSTRALIA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 69. AUSTRALIA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 70. AUSTRALIA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 71. REST OF ASIA-PACIFIC CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 74. LAMEA CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 75. LAMEA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 76. LAMEA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 77. LAMEA CRO SERVICES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 78. BRAZIL CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 79. BRAZIL CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 80. BRAZIL CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 81. SOUTH AFRICA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 82. SOUTH AFRICA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 83. SOUTH AFRICA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 84. SAUDI ARABIA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 85. SAUDI ARABIA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 86. SAUDI ARABIA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 87. REST OF LAMEA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 88. REST OF LAMEA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 89. REST OF LAMEA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 90. BIOTELEMETRY: COMPANY SNAPSHOT
TABLE 91. BIOTELEMETRY: OPERATING BUSINESS SEGMENTS
TABLE 92. BIOTELEMETRY: PRODUCT PORTFOLIO
TABLE 93. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 94. CHARLES RIVER: OPERATING BUSINESS SEGMENTS
TABLE 95. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 96. ICON: COMPANY SNAPSHOT
TABLE 97. ICON: PRODUCT PORTFOLIO
TABLE 98. IQVIA: COMPANY SNAPSHOT
TABLE 99. IQVIA: OPERATING BUSINESS SEGMENTS
TABLE 100. IQVIA: PRODUCT PORTFOLIO
TABLE 101. EVOTEC.: COMPANY SNAPSHOT
TABLE 102. EVOTEC.: OPERATING BUSINESS SEGMENTS
TABLE 103. EVOTEC.: PRODUCT PORTFOLIO
TABLE 104. LABCORP: COMPANY SNAPSHOT
TABLE 105. LABCORP: OPERATING SEGMENTS
TABLE 106. LABCORP: PRODUCT PORTFOLIO
TABLE 107. MEDPACE: COMPANY SNAPSHOT
TABLE 108. MEDPACE: OPERATING BUSINESS SEGMENTS
TABLE 109. MEDPACE: PRODUCT PORTFOLIO
TABLE 110. PRA: COMPANY SNAPSHOT
TABLE 111. PRA: OPERATING SEGMENTS
TABLE 112. PRA: PRODUCT PORTFOLIO
TABLE 113. SYNGENE: COMPANY SNAPSHOT
TABLE 114. SYNGENE: OPERATING BUSINESS SEGMENTS
TABLE 115. SYNGENE: PRODUCT PORTFOLIO
TABLE 116. SYNEOS: COMPANY SNAPSHOT
TABLE 117. SYNEOS: OPERATING SEGMENTS
TABLE 118. SYNEOS: PRODUCT PORTFOLIO
TABLE 01. GLOBAL CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 02. HEALTHCARE CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT, BY REGION, 2018–2026 ($MILLION)
TABLE 03. HEALTHCARE CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 04. CLINICAL DEVELOPMENT SERVICES MARKET BY REGION 2018–2026 ($MILLION)
TABLE 05. CLINICAL DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 06. HEALTHCARE CRO SERVICES MARKET FOR LABORATORY SERVICES MARKET BY REGION 2018–2026 ($MILLION)
TABLE 07. HEALTHCARE CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 08. HEALTHCARE CRO SERVICES MARKET FOR CONSULTING SERVICES BY REGION 2018–2026 ($MILLION)
TABLE 09. HEALTHCARE CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 10. GLOBAL CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 11. ONCOLOGY HEALTHCARE CRO SERVICES, BY REGION, 2018–2026 ($MILLION)
TABLE 12. CRO SERVICES MARKET FOR CNS DISORDER, BY REGION, 2018–2026 ($MILLION)
TABLE 13. CRO SERVICES MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 14. CRO SERVICES MARKET FOR METABOLIC DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 15. CRO SERVICES MARKET FOR INFECTIOUS DISEASE, BY REGION, 2018–2026 ($MILLION)
TABLE 16. HEALTHCARE CRO SERVICES MARKET FOR DIABETES, BY REGION, 2018–2026 ($MILLION)
TABLE 17. CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREA, BY REGION, 2018–2026 ($MILLION)
TABLE 18. GLOBAL CRO SERVICES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 19. CRO SERVICES MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018–2026 ($MILLION)
TABLE 20. CRO SERVICES MARKET, FOR MEDICAL DEVICE, BY REGION, 2018–2026 ($MILLION)
TABLE 21. CARDIOVASCULAR DISEASE CRO SERVICES MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 2018–2026 ($MILLION)
TABLE 22. CRO SERVICES MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 23. NORTH AMERICA CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 24. NORTH AMERICA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 25. NORTH AMERICA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 26. NORTH AMERICA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 27. U.S. CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 28. U.S. CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 29. U.S. CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 30. CANADA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 31. CANADA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 32. CANADA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 33. MEXICO CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 34. MEXICO CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 35. MEXICO CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 36. EUROPE CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 37. EUROPE CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 38. EUROPE CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 39. EUROPE CRO SERVICES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 40. FRANCE CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 41. FRANCE CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 42. FRANCE CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 43. UK CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 44. UK CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 45. U.K CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 46. GERMANY CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 47. GERMANY CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 48. GERMANY CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 49. SPAIN CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 50. SPAIN CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 51. SPAIN CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 52. REST OF EUROPE CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 53. REST OF EUROPE CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 54. REST OF EUROPE CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 55. ASIA-PACIFIC CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 56. ASIA-PACIFIC CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 57. ASIA-PACIFIC CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 58. ASIA-PACIFIC CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 59. JAPAN CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 60. JAPAN CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 61. JAPAN CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 62. CHINA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 63. CHINA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 64. CHINA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 65. INDIA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 66. INDIA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 67. INDIA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 68. AUSTRALIA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 69. AUSTRALIA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 70. AUSTRALIA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 71. REST OF ASIA-PACIFIC CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 73. REST OF ASIA-PACIFIC CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 74. LAMEA CRO SERVICES MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 75. LAMEA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 76. LAMEA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 77. LAMEA CRO SERVICES MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 78. BRAZIL CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 79. BRAZIL CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 80. BRAZIL CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 81. SOUTH AFRICA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 82. SOUTH AFRICA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 83. SOUTH AFRICA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 84. SAUDI ARABIA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 85. SAUDI ARABIA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 86. SAUDI ARABIA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 87. REST OF LAMEA CRO SERVICES MARKET, BY SERVICE TYPE, 2018–2026 ($MILLION)
TABLE 88. REST OF LAMEA CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018–2026 ($MILLION)
TABLE 89. REST OF LAMEA CRO SERVICES MARKET, BY END USER, 2018–2026
TABLE 90. BIOTELEMETRY: COMPANY SNAPSHOT
TABLE 91. BIOTELEMETRY: OPERATING BUSINESS SEGMENTS
TABLE 92. BIOTELEMETRY: PRODUCT PORTFOLIO
TABLE 93. CHARLES RIVER: COMPANY SNAPSHOT
TABLE 94. CHARLES RIVER: OPERATING BUSINESS SEGMENTS
TABLE 95. CHARLES RIVER: PRODUCT PORTFOLIO
TABLE 96. ICON: COMPANY SNAPSHOT
TABLE 97. ICON: PRODUCT PORTFOLIO
TABLE 98. IQVIA: COMPANY SNAPSHOT
TABLE 99. IQVIA: OPERATING BUSINESS SEGMENTS
TABLE 100. IQVIA: PRODUCT PORTFOLIO
TABLE 101. EVOTEC.: COMPANY SNAPSHOT
TABLE 102. EVOTEC.: OPERATING BUSINESS SEGMENTS
TABLE 103. EVOTEC.: PRODUCT PORTFOLIO
TABLE 104. LABCORP: COMPANY SNAPSHOT
TABLE 105. LABCORP: OPERATING SEGMENTS
TABLE 106. LABCORP: PRODUCT PORTFOLIO
TABLE 107. MEDPACE: COMPANY SNAPSHOT
TABLE 108. MEDPACE: OPERATING BUSINESS SEGMENTS
TABLE 109. MEDPACE: PRODUCT PORTFOLIO
TABLE 110. PRA: COMPANY SNAPSHOT
TABLE 111. PRA: OPERATING SEGMENTS
TABLE 112. PRA: PRODUCT PORTFOLIO
TABLE 113. SYNGENE: COMPANY SNAPSHOT
TABLE 114. SYNGENE: OPERATING BUSINESS SEGMENTS
TABLE 115. SYNGENE: PRODUCT PORTFOLIO
TABLE 116. SYNEOS: COMPANY SNAPSHOT
TABLE 117. SYNEOS: OPERATING SEGMENTS
TABLE 118. SYNEOS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL CRO SERVICES MARKET SEGMENTATION
FIGURE 02. LOW-TO- MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 03. LOW BARGAINING POWER OF BUYER
FIGURE 04. MODERATE THREAT OF SUBSTITUTES
FIGURE 05. LOW-TO-MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. HIGH COMPETITIVE RIVALARY
FIGURE 07. TOP INVESTMENT POCKETS
FIGURE 08. TOP PLAYER POSITIONING, 2018
FIGURE 09. DRIVERS AND RESTRAINTS
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF ONCOLOGY CRO SERVICES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR CNS DISORDER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR METABOLIC DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR DIABETES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET, FOR MEDICAL DEVICE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET, FOR ACADEMIC INSTITUTES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. BIOTELEMETRY: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. BIOTELEMETRY: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 22. CHARLES RIVER: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 24. CHARLES RIVER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 25. ICON: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. ICON: REVENUE SHARE BY REGION, 2018(%)
FIGURE 27. IQVIA: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. IQVIA: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 29. IQVIA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 30. EVOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. EVOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32. LABCORP: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. LABCORP: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34. LABCORP: REVENUE SHARE BY REGION, 2018(%)
FIGURE 35. MEDPACE: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. MEDPACE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 37. MEDPACE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 38. PRA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. PRA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 40. PRA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. SYNGENE: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. SYNGENE: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 43. SYNEOS: NET SALES, 2016–2018 ($MILLION)
FIGURE 44. SYNEOS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45. SYNEOS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 01. GLOBAL CRO SERVICES MARKET SEGMENTATION
FIGURE 02. LOW-TO- MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 03. LOW BARGAINING POWER OF BUYER
FIGURE 04. MODERATE THREAT OF SUBSTITUTES
FIGURE 05. LOW-TO-MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. HIGH COMPETITIVE RIVALARY
FIGURE 07. TOP INVESTMENT POCKETS
FIGURE 08. TOP PLAYER POSITIONING, 2018
FIGURE 09. DRIVERS AND RESTRAINTS
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF ONCOLOGY CRO SERVICES MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR CNS DISORDER, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR METABOLIC DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR INFECTIOUS DISEASE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR DIABETES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREA, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET, FOR MEDICAL DEVICE, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CRO SERVICES MARKET, FOR ACADEMIC INSTITUTES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. BIOTELEMETRY: NET SALES, 2016–2018 ($MILLION)
FIGURE 21. BIOTELEMETRY: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 22. CHARLES RIVER: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. CHARLES RIVER: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 24. CHARLES RIVER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 25. ICON: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. ICON: REVENUE SHARE BY REGION, 2018(%)
FIGURE 27. IQVIA: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. IQVIA: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 29. IQVIA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 30. EVOTEC: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. EVOTEC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 32. LABCORP: NET SALES, 2016–2018 ($MILLION)
FIGURE 33. LABCORP: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 34. LABCORP: REVENUE SHARE BY REGION, 2018(%)
FIGURE 35. MEDPACE: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. MEDPACE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 37. MEDPACE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 38. PRA: NET SALES, 2016–2018 ($MILLION)
FIGURE 39. PRA: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 40. PRA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 41. SYNGENE: NET SALES, 2016–2018 ($MILLION)
FIGURE 42. SYNGENE: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 43. SYNEOS: NET SALES, 2016–2018 ($MILLION)
FIGURE 44. SYNEOS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45. SYNEOS: REVENUE SHARE BY REGION, 2018(%)
